RxDoctor Payments Data

Brett Baloun, MD

Gastroenterology · Sioux Falls, SDNPI 1245448869

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 57.5% of the total. Reporting peaked in 2019 at $160 and has fallen 76.4% since, to $38 in 2025. That places this record below the midpoint for gastroenterology clinicians in SD, where the typical reported total is $1,171.

$449in general payments, 2019–2025

Across 29 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$259
  • Gilead$91
  • Amgen$24
  • Aimmune Therapeutics, Inc.$23
  • Sanofi$19
  • Bristol Myers Squibb$17
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$449100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$449 in reported general payments places this provider in the 30th percentile of 41 gastroenterology providers in South Dakota.

See all gastroenterology providers in South Dakota

Medicare billing

Part B allowed, 2024
$83,348
Medicare patients
391
Services billed
621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib24$145,046
CreonLipase/Protease/Amylase24$71,965
LinzessLinaclotide23$19,269
Mesalamine47$17,453
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg341$9,389
Lubiprostone61$7,092
Sucralfate73$4,549
Rabeprazole Sodium122$4,308
Dexlansoprazole DrDexlansoprazole12$3,555
Lansoprazole19$3,088
CholestyramineCholestyramine (With Sugar)25$1,986
Pantoprazole Sodium122$1,889
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates22$1,530
Omeprazole158$1,517
Azathioprine27$1,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Creon, Linzess$259$236,28071 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 41 gastroenterology providers in South Dakota.

Other gastroenterology in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →